{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:42:09Z","timestamp":1787024529391,"version":"build-2736575974"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7779-26","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:10:48Z","timestamp":1784326248000},"source":"Crossref","is-referenced-by-count":1,"title":["Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor\u2013Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma"],"prefix":"10.2169","author":[{"given":"Shinichiro","family":"Minami","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Koshiishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akita University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 75: 960-974, 2021.","DOI":"10.1016\/j.jhep.2021.07.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab for unresectable hepatocellular carcinoma. NEJM Evid 1: 2022.","DOI":"10.1056\/EVIDoa2100070"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yau T, Kang YK, Kim TY, et al. Nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma (CheckMate 040, cohort 4): a multicenter, open-label, phase 1\/2 trial. JAMA Oncol 6: e204564, 2020.","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for advanced hepatocellular carcinoma (CheckMate 9DW): a randomized, open-label, phase 3 trial. Lancet 405: 1851-1864, 2025.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: 2026 update. J Hepatol 84: 631-654, 2026.","DOI":"10.1016\/j.jhep.2025.10.020"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Roessler D, \u00d6cal O, Philipp AB, et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor\u2013based combination therapies: a multicenter retrospective study. J Cancer Res Clin Oncol 149: 3065-3073, 2023.","DOI":"10.1007\/s00432-022-04206-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kim JS, Wong J, Chen SC, et al. Outcomes of nivolumab plus ipilimumab after atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: An international multicenter study. Liver Int 46: e70493, 2025.","DOI":"10.1111\/liv.70493"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Alden SL, Lim M, Kao C, et al. Salvage ipilimumab plus nivolumab after anti\u2013PD-1\/PD-L1 therapy in advanced hepatocellular carcinoma. Cancer Res Commun 3: 1312-1317, 2023.","DOI":"10.1158\/2767-9764.CRC-23-0072"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wong JSL, Kwok GGW, Tang V, et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer 9: e001945, 2021.","DOI":"10.1136\/jitc-2020-001945"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zheng SS, Wu JF, Zhang ZZ, et al. Efficacy and safety of ipilimumab plus anti\u2013PD-1\/PD-L1 antibody combination therapy in advanced hepatocellular carcinoma patients progressing after multiple lines of treatment: a retrospective multicenter study. J Hepatocell Carcinoma 12: 527-537, 2025.","DOI":"10.2147\/JHC.S512302"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sho T, Suda G, Ohara M. Efficacy and Safety of Durvalumab\/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab\/Bevacizumab Treatment. Target Oncol 19: 769-778, 2024.","DOI":"10.1007\/s11523-024-01092-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kim HJ, Hwang SY, Im JW, et al. A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab. J Liver Cancer 23: 213-218, 2023.","DOI":"10.17998\/jlc.2023.02.23"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sasaki A, Kimura R, Okamoto R. Successful treatment with nivolumab plus ipilimumab after progression on durvalumab plus tremelimumab in advanced hepatocellular carcinoma: a case report. Cureus 17: e97530, 2025.","DOI":"10.7759\/cureus.97530"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Silver CR, De la Garza-Ramos C, Stauffer JA, et al. Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab- and bevacizumab-refractory hepatocellular carcinoma resulted in complete pathological response. Radiol Case Rep 19: 5024-5028, 2024.","DOI":"10.1016\/j.radcr.2024.07.157"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cao J, Ding X, Ji J, Zhang L, Luo C. Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced solid tumors: a systematic review and meta-analysis. Front Oncol 14: 1475502, 2024.","DOI":"10.3389\/fonc.2024.1475502"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 75: 47-55, 2017.","DOI":"10.1016\/j.ejca.2017.01.009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ribatti D. Immunosuppressive effects of vascular endothelial growth factor. Oncol Lett 24: 369, 2022.","DOI":"10.3892\/ol.2022.13489"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Da Fonseca LG, Leonardi PC, Hashizume PH, et al. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management, and outcomes. Clin Exp Hepatol 8: 42-48, 2022.","DOI":"10.5114\/ceh.2022.114297"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim JS, Kim Y, Kang B, et al. Organ-specific responses to nivolumab plus ipilimumab in advanced hepatocellular carcinoma: a multicenter, retrospective study. Cancer Med 14: e70997, 2025.","DOI":"10.1002\/cam4.70997"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7779-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:25:50Z","timestamp":1784345150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7779-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7779-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7779-26"}}